Categories AlphaGraphs, Earnings, Technology

HubSpot beats Q2 views; stock gains on strong FY19 outlook

HubSpot’s (NYSE: HUBS) second quarter 2019 earnings and revenue beat consensus estimates. The company also lifted its earnings and revenue outlook for fiscal 2019. HubSpot stock was trading up about 7% in the extended hours of trading.

Non-GAAP net income was $17.6 million, or $0.37 per share, compared to $7.4 million, or $0.18 per share in the second quarter of 2018. Revenue soared 33% year-over-year to $163 million. Analysts had expected HubSpot to report earnings of $0.25 per share on revenue of $157.26 million.

HubSpot grew total customers to 64,836 at June 30, 2019, up 35% from June 30, 2018

The Cambridge, Massachusetts-based firm GAAP net loss was $17.4 million, or $0.41 per share, compared to a loss of $18.2 million, or $0.48 per share in Q2 2018.

The company lifted its outlook for fiscal 2019. Adjusted EPS is now expected to be in the range of $1.39 to $1.41 versus the prior guide of $1.26 to $1.30. Revenue for 2019 is now expected to be between $663 million and $665 million compared to the previous outlook range of $655.5 million to $658.5 million.

Read: Cognizant’s Q2 results tops estimates; stock advances

For the third quarter of 2019, HubSpot expects adjusted EPS to be in the range of $0.22 to $0.24 and revenue is projected to be in the range of $168 million to $169 million.

HubSpot grew total customers to 64,836 at June 30, 2019, up 35% from June 30, 2018. Total average subscription revenue per customer was $9,913 during the second quarter of 2019, down 1% compared to the prior-year quarter.

HubSpot stock has gained 31% since the beginning of this year and had dropped 9% in the past three months.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top